Methyl-3-isopropoxypropionat | 62599-53-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Methyl-3-isopropoxypropionat
• 英文别名: 3-isopropoxy-propionic acid methyl ester；O-Isopropyl-hydracrylsaeure-methylester；3-Isopropoxy-propionsaeure-methylester；3-Isopropyloxy-propionsaeure-methylester；Methyl 3-[(propan-2-yl)oxy]propanoate；methyl 3-propan-2-yloxypropanoate
• CAS: 62599-53-5
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: NOJJPZGRFJRYCY-UHFFFAOYSA-N

物化性质

• 沸点：
  182.0±13.0 °C(Predicted)
• 密度：
  0.947±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Process of preparing unsaturated carboxylic acid amides
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0321256A2

  公开（公告）日：1989-06-21

  A process is provided for the preparation of an N-substituted unsaturated carboxylic acid amide represented by the following formula: wherein R¹ means a hydrogen atom or methyl group, Y denotes a methylene group, oxygen atom or methylimino group, m and n stand individually for an integer of 0­-5, and m + n is an integer of 3-5. The process comprises reacting a specified β-alkoxy-substituted carboxylate with a specified cyclic amine to form a β-alkoxy-substituted carboxylic acid amide compound and then removing an alcohol from the carboxylic acid amide compound in the presence of a basic catalyst to form an unsaturated group.

  本发明提供了一种制备下式所代表的 N-取代不饱和羧酸酰胺的工艺： 其中 R¹ 表示氢原子或甲基，Y 表示亚甲基、氧原子或甲基亚氨基，m 和 n 分别表示 0-5 的整数，m+n 为 3-5 的整数。该工艺包括使指定的β-烷氧基取代的羧酸酯与指定的环胺反应生成β-烷氧基取代的羧酸酰胺化合物，然后在碱性催化剂存在下从羧酸酰胺化合物中除去醇以形成不饱和基团。
• CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF
  申请人：Eisai Co., Ltd.

  公开号：EP1380562A1

  公开（公告）日：2004-01-14

  The present invention provides a novel carboxylic acid compound, a salt thereof or a hydrate of them useful as an insulin sensitizer, and a medicament comprising the compound as an active ingredient. That is, the present invention provides a carboxylic acid compound represented by the following formula, a salt thereof, an ester thereof or a hydrate of them. Wherein R1 represents a hydrogen atom, hydroxyl group, halogen, carboxyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents; L represents a single bond, or a C1-6 alkylene group, a C2-6 alkenylene group or a C2-6 alkynylene group, each of which may have one or more substituents; M represents a single bond, or a C1-6 alkylene group, a C2-6 alkenylene group or a C2-6 alkynylene group, each of which may have one or more substituents; T represents a single bond, or a C1-3 alkylene group, a C2-3 alkenylene group or a C2-3 alkynylene group, each of which may have one or more substituents; W represents a carboxyl group; - - - represents a single bond etc. ; X represents a single bond, oxygen atom, a group represented by -NRX1CQ1O- (wherein Q1 represents an oxygen atom or sulfur atom; and RX1 represents a hydrogen atom, formyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents), -OCQ1NRX1- (wherein Q1 and RX1 are as defined above), -CQ1NRx1O- (wherein Q1 and RX1 are as def ined above), ONRX1CQ1- (wherein Q1 and RX1 are as defined above), - Q2SO2- (wherein Q2 is an oxygen atom or -NRX10- (wherein RX10 represents a hydrogen atom, formyl group, or a C1-6 alkyl group etc., each of which may have one or more substituents)) or -SO2Q2- (wherein Q2 is as defined above), (wherein, provided that RX2 and RX3, and/or RX4 and RX5 may together form a ring, Q3 and Q4 are the same as or different from each other and each represents an oxygen atom, (O)S(O) or NRX10 (wherein NRX10 is as defined above)); Y represents a 5- to 14-membered aromatic group etc., which may have one or more substituents and one or more hetero atoms; and the ring Z represents a 5-to 14-membered aromatic group which may have 0 to 4 substituents and one or more hetero atoms, and wherein part of the ring may be saturated.

  本发明提供了一种可用作胰岛素增敏剂的新型羧酸化合物、其盐或其水合物，以及包含该化合物作为活性成分的药物。也就是说，本发明提供了由下式代表的羧酸化合物、其盐、其酯或它们的水合物。 其中 R1 代表氢原子、羟基、卤素、羧基或 C1-6 烷基等、L 代表单键，或 C1-6 亚烷基、C2-6 亚烯基或 C2-6 亚炔基，其中每个基团可带有一个或多个取代基；M 代表单键，或 C1-6 亚烷基、C2-6 亚烯基或 C2-6 亚炔基，其中每个基团可有一个或多个取代基； T 代表单键，或 C1-3 亚烷基、C2-3 亚烯基或 C2-3 亚炔基，其中每个基团可有一个或多个取代基； W 代表羧基； - - - 代表单键等；X 代表单键、氧原子、由 -NRX1CQ1O- 代表的基团（其中 Q1 代表氧原子或硫原子；RX1 代表氢原子、甲酰基或 C1-6 烷基等）、其中每个取代基可有一个或多个）、-OCQ1NRX1-（其中 Q1 和 RX1 如上定义）、-CQ1NRx1O-（其中 Q1 和 RX1 如上定义）、ONRX1CQ1-（其中 Q1 和 RX1 如上定义）、-Q2SO2-（其中 Q2 是氧原子或-NRX10-（其中 RX10 代表氢原子、甲酰基或 C1-6 烷基等、其中每个基团可具有一个或多个取代基））或-SO2Q2-（其中 Q2 如上定义）、 (其中，只要 RX2 和 RX3，和/或 RX4 和 RX5 可共同形成一个环，Q3 和 Q4 彼此相同或不同，且各自代表氧原子、（O）S（O）或 NRX10（其中 NRX10 如上定义））；Y 代表 5 至 14 元芳香基团等、环 Z 代表 5 至 14 元芳香基团，可具有 0 至 4 个取代基和一个或多个杂原子，其中部分环可为饱和环。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF BCR-ABL POSITIVE LYMPHOBLASTIC LEUKEMIAS
  申请人：ST. JUDE CHILDREN'S RESEARCH HOSPITAL

  公开号：US20150133462A1

  公开（公告）日：2015-05-14

  In one aspect, the invention relates to compositions comprising BCR-ABL tyrosine kinase inhibitors and artemisinin analogues, derivatives thereof, or related compounds, which are useful as in treating Philadelphia chromosome positive leukemias; pharmaceutical compositions comprising the compounds; and methods of treating disorders of uncontrolled cellular proliferation associated with BCR-ABL dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• US4978754A
  申请人：——

  公开号：US4978754A

  公开（公告）日：1990-12-18
• US6415614B1
  申请人：——

  公开号：US6415614B1

  公开（公告）日：2002-07-09